Ratio Therapeutics, PanTera strike Ac-225 supply agreement

Ratio Therapeutics has signed a supply agreement with PanTera for actinium-225 (Ac-225), a radioisotope used in targeted alpha therapy. The deal aims to secure the radiopharmaceutical pipeline for cancer treatment.

• The agreement involves the supply of Ac-225, a key isotope for targeted alpha therapies.
• This partnership may address growing demand for radiopharmaceuticals in nuclear medicine.
• Further details of the agreement were not disclosed in the announcement.

RadPigeon summaries are original and for information only. They are not clinical advice.